Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility

[1]  A. López-Soto,et al.  NKG2D signaling in cancer immunosurveillance , 2015, International journal of cancer.

[2]  M. Kasahara,et al.  Immunohistochemical Validation and Expression Profiling of NKG2D Ligands in a Wide Spectrum of Human Epithelial Neoplasms , 2015, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[3]  D. Campana,et al.  Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer , 2014, International journal of cancer.

[4]  A. López-Soto,et al.  Molecular Bases for the Regulation of NKG2D Ligands in Cancer , 2014, Front. Immunol..

[5]  A. Santoni,et al.  The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells , 2014, Front. Immunol..

[6]  B. Seliger,et al.  The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer , 2013, The Journal of Immunology.

[7]  O. Janssen,et al.  Shedding of endogenous MHC class I‐related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17 , 2013, International journal of cancer.

[8]  T. Spies,et al.  Immunobiology and Conflicting Roles of the Human NKG2D Lymphocyte Receptor and Its Ligands in Cancer , 2013, The Journal of Immunology.

[9]  O. Janssen,et al.  Generation of Soluble NKG2D Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications , 2013, Scandinavian journal of immunology.

[10]  L. Rodrigo,et al.  Regulation of NKG2D signaling during the epithelial-to-mesenchymal transition , 2013, Oncoimmunology.

[11]  F. Vizoso,et al.  Cytokines related to MMP-11 expression by inflammatory cells and breast cancer metastasis , 2013, Oncoimmunology.

[12]  Jack Gauldie,et al.  Inflammation Induced by MMP-9 Enhances Tumor Regression of Experimental Breast Cancer , 2013, The Journal of Immunology.

[13]  A. G. de Herreros,et al.  Epithelial–Mesenchymal Transition Induces an Antitumor Immune Response Mediated by NKG2D Receptor , 2013, The Journal of Immunology.

[14]  Michael Hagemann-Jensen,et al.  Regulation of NKG2D-ligand cell surface expression by intracellular calcium after HDAC-inhibitor treatment. , 2013, Molecular immunology.

[15]  N. Stanietsky,et al.  MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. , 2012, Cancer research.

[16]  Eric Vivier,et al.  Targeting natural killer cells and natural killer T cells in cancer , 2012, Nature Reviews Immunology.

[17]  Jae Kwon Lee,et al.  Importance of NKG2D-NKG2D ligands interaction for cytolytic activity of natural killer cell. , 2012, Cellular immunology.

[18]  B. Seliger,et al.  HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines , 2012, The Journal of Immunology.

[19]  Dahui Sun,et al.  MMP9 mediates MICA shedding in human osteosarcomas , 2011, Cell biology international.

[20]  R. Solana,et al.  NK Cell Recognition and Killing of Melanoma Cells Is Controlled by Multiple Activating Receptor-Ligand Interactions , 2011, Journal of Innate Immunity.

[21]  F. Locatelli,et al.  Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. , 2011, Blood.

[22]  M. Caligiuri,et al.  Innate or Adaptive Immunity? The Example of Natural Killer Cells , 2011, Science.

[23]  Per Albertsson,et al.  Matrix Metalloproteinases in Cytotoxic Lymphocytes Impact on Tumour Infiltration and Immunomodulation , 2010, Cancer Microenvironment.

[24]  L. Lanier,et al.  Effect of NKG2D ligand expression on host immune responses , 2010, Immunological reviews.

[25]  Gang Liu,et al.  Cutting Edge: The Membrane Type Matrix Metalloproteinase MMP14 Mediates Constitutive Shedding of MHC Class I Chain-Related Molecule A Independent of A Disintegrin and Metalloproteinases , 2010, The Journal of Immunology.

[26]  G. Ball,et al.  NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting , 2009, Clinical Cancer Research.

[27]  N. Hayashi,et al.  Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma. , 2009, Cancer research.

[28]  Insiya Jafferji,et al.  Beyond Stressed Self: Evidence for NKG2D Ligand Expression on Healthy Cells. , 2009, Current immunology reviews.

[29]  A. Cerwenka,et al.  NKG2D ligands in tumor immunity , 2008, Oncogene.

[30]  H. Rammensee,et al.  Tumor-associated MICA is shed by ADAM proteases. , 2008, Cancer research.

[31]  M. Mason,et al.  Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression1 , 2008, The Journal of Immunology.

[32]  N. Greenberg,et al.  NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. , 2008, Immunity.

[33]  L. Frati,et al.  Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis. , 2007, Blood.

[34]  A. Vaheri,et al.  Cell‐cell contact activation of fibroblasts increases the expression of matrix metalloproteinases , 2006, Annals of medicine.

[35]  L. Matrisian,et al.  Matrix metalloproteinases: they're not just for matrix anymore! , 2001, Current opinion in cell biology.

[36]  T. Spies,et al.  Broad tumor-associated expression and recognition by tumor-derived γδ T cells of MICA and MICB , 1999 .

[37]  S. Bauer,et al.  Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. , 1999, Proceedings of the National Academy of Sciences of the United States of America.